Last Updated: November 16, 2026

Drug Sales Trends for HUMULIN N

« Back to Dashboard


Drug Sales Revenue Trends for HUMULIN N
Drug Units Sold Trends for HUMULIN N

Humulin N Market Analysis and Sales Projections

Last updated: September 9, 2026

Humulin N is Eli Lilly’s intermediate-acting human insulin formulation containing recombinant human insulin isophane, commonly called NPH insulin. Its commercial market is mature, price-sensitive, and structurally declining in developed countries as patients and prescribers shift toward insulin analogs, continuous glucose monitoring, and newer diabetes therapies. Humulin N retains demand because it is inexpensive, widely understood, available in vial and KwikPen presentations, and included in many public-sector diabetes formularies.

Lilly does not separately report Humulin N revenue in its public financial statements. The company reports Humulin within broader insulin and diabetes portfolios, preventing a company-confirmed product-level sales estimate. The projection below is therefore a market-based scenario model rather than Lilly guidance.

What is Humulin N and how is it used?

Humulin N is an intermediate-acting insulin designed to provide basal glycemic control. The product is administered subcutaneously and has a slower onset and longer duration than regular human insulin. It is used in adults and pediatric patients with diabetes mellitus when insulin therapy is required (Eli Lilly and Company, 2024).

Product attribute Humulin N profile
Active ingredient Human insulin isophane, NPH
Manufacturer Eli Lilly and Company
Drug class Intermediate-acting human insulin
Primary use Basal insulin treatment for diabetes
Major dosage forms U-100 vial; U-100 prefilled pen in selected markets
Administration Subcutaneous injection
Primary competitors Novolin N, ReliOn/NPH products, insulin glargine, insulin detemir, biosimilar and follow-on basal insulins
Regulatory status FDA-approved prescription insulin
Commercial position Mature branded human-insulin product

Humulin N is distinct from Humulin R, which is short-acting regular human insulin, and Humulin 70/30, a premixed formulation combining NPH and regular human insulin.

What is the market size for NPH insulin?

The global NPH insulin market is a small segment of the broader insulin market. Public market reports often combine NPH with human insulin or basal insulin, producing inconsistent estimates. A reasonable 2024 global market estimate for branded and generic NPH insulin is approximately $1.0 billion to $1.5 billion in manufacturer revenue, with the majority of value concentrated in the United States, Western Europe, Japan, and selected emerging markets.

The broader global insulin market is materially larger, commonly estimated at more than $20 billion annually, but rapid-acting and long-acting analogs account for most value (IQVIA, 2024; International Diabetes Federation, 2021).

Estimated NPH insulin market by region

Region 2024 estimated NPH market share Market characteristics
United States 35%-45% High list prices but heavy rebates and discount programs
Europe 20%-25% Lower prices, tender procurement, declining analog substitution
Latin America 10%-15% Public procurement and affordability support NPH demand
Asia-Pacific 15%-20% Large patient population and mixed use of human insulin and analogs
Middle East and Africa 8%-12% Public-sector purchasing and access constraints

The United States produces a disproportionate share of reported revenue because insulin list prices are higher than in most international markets. Net prices are lower because of rebates, Medicaid discounts, 340B pricing, Medicare negotiations, copay assistance, and institutional contracting.

What are Humulin N sales and revenue projections?

Lilly does not disclose Humulin N sales as a standalone line item. The product is included within broader insulin revenue and may be reported alongside Humulin R, Humulin 70/30, and other diabetes products.

The following forecast estimates global manufacturer revenue attributable to Humulin N, including branded Humulin N and associated commercial channels. It excludes downstream pharmacy margins and patient out-of-pocket payments.

Humulin N revenue forecast

Year Bear case Base case Upside case
2024 $300 million $400 million $500 million
2025 $270 million $370 million $485 million
2026 $240 million $345 million $470 million
2027 $215 million $320 million $455 million
2028 $190 million $300 million $440 million
2029 $170 million $280 million $425 million

The base case implies a compound annual decline of approximately 6% from 2024 through 2029. The bear case assumes faster conversion to basal insulin analogs and further net-price compression. The upside case assumes continued public-sector demand, stronger use of lower-cost human insulin, and stable access in emerging markets.

These figures should be treated as market estimates rather than Lilly forecasts. Lilly’s actual revenue could differ because of product-level transfer pricing, channel mix, geographic reporting, and portfolio accounting.

Main revenue drivers

Humulin N revenue depends on five factors:

  1. Patient volume using NPH insulin.
  2. Net price after rebates and public-sector discounts.
  3. Geographic mix, particularly the United States versus tender markets.
  4. Conversion rates to insulin glargine, insulin degludec, and other basal analogs.
  5. Availability of vial and pen presentations.

Unit volume is likely to decline more slowly than revenue because NPH remains a low-cost option for patients who cannot access or afford analog insulin. Revenue erosion is accelerated by price reductions and government procurement.

When does Humulin N lose exclusivity?

Humulin N no longer has meaningful market exclusivity based on an active composition-of-matter patent. The underlying recombinant human insulin technology and NPH formulation patents expired many years ago. The product is therefore commercially protected by manufacturing capability, regulatory history, brand recognition, distribution, and device access rather than by a current core patent monopoly.

What is the Orange Book status of Humulin N?

Humulin N is an FDA-approved drug, but no currently material active patent estate is generally associated with the core NPH insulin product in the manner seen with newer branded medicines. The FDA Orange Book should be checked for the applicable product listing and any current patent or exclusivity entry because listings can vary by presentation and regulatory update (U.S. Food and Drug Administration, 2024a).

The practical conclusion is that Humulin N is not a patent-protected growth asset. Its commercial defense is operational rather than legal.

Are there Paragraph IV challenges to Humulin N?

Paragraph IV litigation risk for Humulin N is limited because the core product is old and competitors have long marketed NPH insulin. The principal competitive mechanism is abbreviated or follow-on insulin approval, not a new Paragraph IV challenge against a recently issued patent.

For insulin products, FDA approval pathways can involve complex requirements relating to sameness, manufacturing, device compatibility, and interchangeability. The Biologics Price Competition and Innovation Act also created a pathway for insulin products to be regulated as biologics, although the commercial and legal framework differs from a conventional small-molecule generic (U.S. Food and Drug Administration, 2024b).

Potential entry risks include:

  • A competing NPH vial approved at a lower price.
  • A pen presentation with improved payer access.
  • Private-label or authorized-generic distribution.
  • Government tender substitution.
  • Hospital and pharmacy benefit manager formulary exclusion.
  • Patient conversion to lower-cost human insulin alternatives.

Which companies compete with Humulin N?

The main direct competitor is Novo Nordisk’s Novolin N. Walmart’s ReliOn insulin products and other human-insulin suppliers compete primarily on price. Basal insulin analogs compete for the same treatment role but are not direct NPH substitutes in every patient or payer segment.

Competitor Product type Competitive effect
Novolin N NPH human insulin Direct branded competitor
ReliOn NPH and equivalent products Low-cost NPH Strong price pressure in the U.S.
Insulin glargine Long-acting analog Main clinical substitution threat
Insulin degludec Ultra-long-acting analog Premium basal alternative
Insulin detemir Long-acting analog Historical competitor, declining availability in some markets
Premixed human insulin NPH-containing formulations Alternative for patients requiring combined basal and mealtime coverage

The commercial competition is segmented. NPH generally wins on acquisition cost. Basal analogs often win on dosing convenience, hypoglycemia profile, duration, and physician familiarity.

How strong is the Humulin N patent estate?

The Humulin N patent estate is weak as a current exclusivity asset but strong as a manufacturing and regulatory platform.

Patent strength

Category Assessment
Core composition patent Expired or commercially immaterial
NPH formulation protection Expired or commercially immaterial
Method-of-use patents No material current barrier identified for routine NPH use
Device patents Presentation-specific and unlikely to block vial competition
Manufacturing know-how Potentially important
Regulatory data package Historical value, but not a substantial modern exclusivity barrier
Brand and distribution More important than patent rights
Litigation leverage Low

Manufacturing know-how can still create practical barriers. Recombinant insulin production requires validated cell culture, purification, folding, formulation, sterile filling, quality control, and regulatory comparability. These barriers can delay entry or reduce the number of credible suppliers, but they do not create durable exclusivity comparable to an active patent.

What formulation and device protections affect Humulin N?

Humulin N is sold primarily in vial and pen formats. Presentation-specific intellectual property may relate to:

  • Pen injector architecture.
  • Cartridge and stopper design.
  • Dose-setting mechanisms.
  • Container-closure systems.
  • Manufacturing and fill-finish processes.
  • Stability and storage conditions.

These rights are unlikely to prevent competition with NPH supplied in a vial. Device rights matter more when a competitor seeks to copy a specific pen presentation. A competing NPH vial can avoid many device-related claims.

The pen format can improve convenience and reduce dosing errors, but it also carries higher manufacturing and distribution costs. In price-sensitive markets, the vial is likely to remain the principal commercial format.

What FDA regulatory issues affect Humulin N?

Humulin N has an established FDA approval and long safety history. Regulatory risk is therefore low relative to newer biologic products. The key regulatory issues are manufacturing consistency, sterile production, labeling, device performance, storage requirements, and substitution rules.

Insulin products must maintain tight quality specifications because changes in potency, impurities, aggregation, or delivery-device performance can affect glucose control. The FDA has emphasized insulin interchangeability and biosimilar pathways as part of the transition of insulin products to the biologics framework (U.S. Food and Drug Administration, 2024b).

For Humulin N, FDA risk is more likely to arise from supply disruption or manufacturing observations than from clinical efficacy uncertainty.

What generic launch scenarios exist for Humulin N?

Scenario 1: Stable branded demand

Lilly maintains broad distribution, patient assistance, and payer access. Humulin N volume declines gradually, while pricing remains stable in contracted channels. This scenario supports the base forecast.

Scenario 2: Accelerated price competition

A low-cost NPH supplier expands distribution through retail pharmacies and government channels. Lilly responds with lower net pricing. Revenue declines faster than unit volume.

Scenario 3: Formulary displacement

Large payers place lower-cost NPH products or alternative basal insulins on preferred tiers. Humulin N loses prescriptions despite maintaining regulatory status and supply.

Scenario 4: Emerging-market resilience

NPH remains a preferred public-sector insulin because of affordability. Volume growth in lower-income markets partly offsets declining use in the United States and Europe.

The most likely outcome is gradual revenue erosion rather than an abrupt loss of market share. Humulin N has no major patent cliff ahead because the principal exclusivity period ended long ago.

What licensing deals affect Humulin N?

No major recent licensing transaction is required to commercialize Humulin N. Lilly controls the product’s principal manufacturing and branding rights. The relevant commercial relationships are more likely to involve wholesalers, pharmacy benefit managers, public procurement agencies, retail programs, and patient-access partners than third-party patent licenses.

Any contract manufacturing or regional distribution arrangement could affect reported revenue, but public disclosures do not provide a product-level map of such arrangements.

What litigation affects Humulin N?

Humulin N is not generally associated with active, high-value patent litigation comparable to litigation involving newer insulin analogs, delivery devices, or combination products. The primary legal risks are commercial:

  • Product liability claims.
  • Manufacturing and quality disputes.
  • Patent disputes involving injector devices.
  • Contract disputes with distributors or payers.
  • Regulatory enforcement involving labeling or manufacturing controls.

The absence of a major active patent case reduces litigation-related launch uncertainty for competing NPH products.

How does Humulin N compare with insulin glargine?

Attribute Humulin N Insulin glargine
Insulin type Human insulin, NPH Long-acting insulin analog
Price position Low to moderate Historically premium, now reduced by biosimilar competition
Dosing profile More variable More predictable basal profile
Hypoglycemia risk Generally higher, particularly nocturnal Generally lower in many comparative settings
Dosing frequency Often once or twice daily Usually once daily
Market trend Declining Larger and more durable market
Patent position Mature, largely expired Originator and follow-on patent estates vary
Main advantage Affordability Convenience and pharmacokinetic profile

Humulin N is likely to retain a role in cost-constrained treatment settings. Insulin glargine is better positioned for commercial growth, although biosimilar competition and payer price pressure are reducing its revenue potential.

What is the outlook for Humulin N through 2029?

Humulin N should remain commercially viable through 2029, but it is unlikely to be a growth product for Lilly. The base case is a 5%-7% annual revenue decline, driven by analog substitution, low-cost competition, and public-sector price pressure.

The product’s strongest defenses are:

  • Low acquisition cost relative to analogs.
  • Long clinical experience.
  • Broad prescriber familiarity.
  • Established global manufacturing.
  • Continued use in public programs.
  • Availability in a simple vial presentation.

Its principal weaknesses are:

  • No meaningful current patent exclusivity.
  • Greater dosing variability than newer basal analogs.
  • Higher hypoglycemia concerns in some patients.
  • Limited pricing power.
  • Competition from both low-cost NPH and premium analogs.

Key Takeaways

  • Humulin N is a mature NPH human-insulin product marketed by Eli Lilly.
  • Lilly does not separately disclose Humulin N revenue.
  • Estimated 2024 global manufacturer revenue is approximately $300 million to $500 million, with a base case of $400 million.
  • Base-case revenue declines to approximately $280 million by 2029.
  • The product has no material current core patent barrier.
  • Orange Book and Paragraph IV risks are limited compared with newer insulin products.
  • Novolin N and low-cost private-label NPH are the principal direct competitors.
  • Insulin glargine and other basal analogs are the main clinical substitution threat.
  • Manufacturing capability, supply reliability, payer access, and brand recognition matter more than patent rights.
  • Humulin N is likely to remain commercially relevant in cost-sensitive and public-sector markets despite declining developed-market use.

FAQs

Is Humulin N interchangeable with Novolin N?

Both products contain NPH human insulin, but interchangeability depends on applicable FDA rules, product labeling, physician direction, and payer policy. Patients should not switch products without clinical supervision.

Is Humulin N cheaper than insulin glargine?

Humulin N is generally positioned as a lower-cost insulin option, although actual patient cost depends on insurance coverage, rebates, pharmacy pricing, assistance programs, and product presentation.

Can a generic company launch NPH insulin without a license from Lilly?

A competitor can seek regulatory approval and commercialize NPH insulin without licensing Lilly’s expired core technology, provided it satisfies FDA manufacturing, quality, labeling, and approval requirements.

Does Humulin N have biosimilar competition?

NPH insulin has long faced competition from other human-insulin products. The FDA’s biologic framework also permits follow-on and interchangeable insulin products, subject to applicable regulatory standards.

Is Humulin N a growth opportunity for pharmaceutical investors?

Humulin N is primarily a cash-generation and access product rather than a growth asset. Its investment profile depends on manufacturing efficiency, channel economics, public-sector demand, and Lilly’s ability to manage price erosion.

References

Eli Lilly and Company. (2024). Humulin N prescribing information. https://pi.lilly.com

International Diabetes Federation. (2021). IDF diabetes atlas (10th ed.). https://diabetesatlas.org

IQVIA. (2024). The global use of medicines 2024: Outlook to 2028. IQVIA Institute for Human Data Science.

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

U.S. Food and Drug Administration. (2024b). Insulin and insulin products. https://www.fda.gov/drugs/biosimilars/insulin-and-insulin-products

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.